World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
34924
World Ranking
11207
National Ranking
409

Pellegrino Musto publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Pellegrino Musto sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 931 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Pellegrino Musto D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Pellegrino Musto sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Pellegrino Musto is affiliated with the University of Bari Aldo Moro in Italy. The primary field of their research is Medicine, with a focus on subfields such as Hematology, Molecular Biology, Oncology, Genetics, and Infectious Diseases.

Their research covers several main topics including:

  • Multiple Myeloma Research and Treatments
  • Acute Myeloid Leukemia Research
  • Protein Degradation and Inhibitors
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • SARS-CoV-2 and COVID-19 Research

Pellegrino Musto has contributed to numerous publications in a variety of venues. Their frequent publication venues include:

  • Blood
  • HemaSphere
  • Hematological Oncology
  • Haematologica
  • Cancers

Several recurring coauthors have collaborated extensively with them, including:

  • Giorgina Specchia
  • Francesco Albano
  • Mario Boccadoro
  • Nicola Sgherza
  • Francesca Gay

Notable recent papers authored include:

  • Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study (2020, The Lancet Haematology)
  • Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021, Blood Cancer Journal)
  • Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network (2023, The Lancet Oncology)
  • High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (2022, Journal of Clinical Oncology)
  • Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial (2022, The Lancet Oncology)

Best Publications

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • BRAF mutations in hairy-cell leukemia

    Enrico Tiacci;Vladimir Trifonov;Gianluca Schiavoni;Antony Holmes

  • Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

    Antonio Palumbo;Sara Bringhen;Tommaso Caravita;Emanuela Merla

  • Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

    Roberto Marchioli;Guido Finazzi;Giorgina Specchia;Rossella Cacciola

  • Autologous transplantation and maintenance therapy in multiple myeloma

    Antonio Palumbo;Federica Cavallo;Francesco Di Raimondo

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

    Philip L. McCarthy;Sarah A. Holstein;Maria Teresa Petrucci;Paul G. Richardson

  • Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

    Antonio Palumbo;Sara Bringhen;Davide Rossi;Maide Cavalli

  • Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.

    Francesco Passamonti;Chiara Cattaneo;Luca Arcaini;Riccardo Bruna

  • Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

    Sara Bringhen;Alessandra Larocca;Davide Rossi;Maide Cavalli

  • Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

    Antonio Palumbo;Sara Bringhen;Anna M. Liberati;Tommaso Caravita

  • Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

    Michele Cavo;Lucia Pantani;Maria Teresa Petrucci;Francesca Patriarca

  • European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

    Evangelos Terpos;Martina Kleber;Monika Engelhardt;Sonja Zweegman

  • Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

    Antonio Palumbo;Patrizia Falco;Paolo Corradini;Antonietta Falcone

  • Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

    Antonio Palumbo;Sara Bringhen;Maria Teresa Petrucci;Pellegrino Musto

  • Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.

    Livio Pagano;Caterina Giovanna Valentini;Alessandro Pulsoni;Simona Fisogni

  • Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study

    Alfonso Mele;Alessandro Pulsoni;Elvira Bianco;Pellegrino Musto

  • ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

    Massimo Federico;Stefano Luminari;Emilio Iannitto;Giuseppe Polimeno

  • Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

    Peter M. Fayers;Peter M. Fayers;Antonio Palumbo;Cyrille Hulin;Anders Waage

  • Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

    Alessandra Larocca;Pierre Wijermans;Federica Cavallo

Frequent Co-Authors

Antonio Palumbo
Antonio Palumbo University of Turin
Mario Boccadoro
Mario Boccadoro University of Turin
Maria Teresa Petrucci
Maria Teresa Petrucci Sapienza University of Rome
Francesco Di Raimondo
Francesco Di Raimondo University of Catania
Michele Cavo
Michele Cavo University of Bologna
Gianluca Gaidano
Gianluca Gaidano University of Eastern Piedmont Amadeo Avogadro
Antonino Neri
Antonino Neri University of Milan
Paolo Corradini
Paolo Corradini University of Milan
Giorgina Specchia
Giorgina Specchia University of Bari Aldo Moro
Federica Cavallo
Federica Cavallo University of Turin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens up various educational routes beyond the traditional MD. Many students explore flexible online nursing degrees as both an entry point to healthcare and a stepping-stone for future advancement. For those seeking convenience and affordability, a nursing degree online offers foundational courses and practical experience, often with lower tuition costs.

Registered nurses looking to advance their careers often pursue a Bachelor of Science in Nursing. The cheapest rn to bsn online programs allow RNs to increase their qualifications flexibly and affordably, without putting their careers on hold.

For those aiming for senior clinical or academic roles, a Doctor of Nursing Practice (DNP) can be a good choice. The cheapest dnp online program list helps find cost-effective options for building leadership and research skills in nursing.

If you hold a non-nursing bachelor’s degree but want to become a nurse practitioner, direct entry nurse practitioner programs for non-nurses online provide an accelerated path into advanced practice nursing, making the transition to a medical career more accessible than ever.

Best Scientists Citing Pellegrino Musto

Trending Scientists

Recently Published Articles